Our client is a multinational pharmaceutical company with over 25 locations worldwide. They have a large product portfolio that currently includes over 30 products covering a broad array of indications.

They wish to in-license specialty pharmaceutical products for the following market segments:

  • In the United States our client is interested in products for In Vitro Fertilization (IVF) Clinics and Inborn Errors of Metabolism (IEM).
  • In Europe they are focused in the hospital / emergency medicine segments.

United States:

Interest in marketed products with US FDA approval. They are open to considering pharmaceuticals, medical foods, and medical devices for IVF clinics and IEMs. Products of highest interest should include off-patent molecules, with new formulations and/or new indications representing the key value proposition. New Chemical Entities (NCEs) or completely novel delivery mechanisms are not currently of interest.


Target companies / products should be located in, or focused on, the following European market segments:

  • UK
  • Ireland
  • Nordics
  • Northern Europe (especially Germany and Benelux)

Companies / products should be focused in the acute hospital care, emergency departments, pre-hospital (ambulances), critical care, ENT or IEMs.

Client interest is in outright acquisition of candidate company(s) / product(s).

Successful products on the market are preferred, however, preregistration products are acceptable.